Treatment options for Advanced Heart Failure (AHF) are increasing in number and complexity and now include devices delivered surgically, through the skin, or as part of hybrid procedures involving both cardiac surgeons and interventional cardiologists. Currently, interventional cardiology training does not include training in AHF. For the majority of interventional cardiologists, AHF training is not required. However, for a growing number of interventional cardiologists, an additional year of in-depth training in Advanced Heart Failure and Transplant Cardiology (AHFTC) will provide the knowledge to make optimal decisions for patients with AHF who are being considered for drug or device therapy and be dual board eligible.
The group of interventional heart failure specialists will be uniquely positioned to evaluate and implement emerging drug- and device-based therapies for the management of all subtypes of heart failure, including heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), valvular heart failure, right ventricular failure, pulmonary hypertension, cardiorenal syndrome, acute decompensated HF, cardiogenic shock and complication associated with left ventricular assist devices.
